Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
29.01.24
/
50%
€21.00
Target price
29.01.25
€28.68
Performance (%)
-13.81%
Price
02.05.24
€18.10
Summary
This prediction is currently active. The price of Myriad Genetics has decreased since the start of the prediction. Compared to the start price this results in a performance of -13.81%. This prediction currently runs until 29.01.25. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Myriad Genetics | 9.697% | 9.697% |
iShares Core DAX® | -0.922% | -1.993% |
iShares Nasdaq 100 | 0.371% | -0.868% |
iShares Nikkei 225® | 2.224% | -5.187% |
iShares S&P 500 | -0.026% | -0.918% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat